Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Takeda
Takeda
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Takeda's NDA for metastatic colorectal cancer treatment
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance
Takeda Pharmaceutical to acquire GammaDelta Therapeutics
Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance
Takeda to evaluate Aptamer Group reagents for drug development
Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance
Adaptate Biotherapeutics raises $18 m in Series A2 funding
The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance
Novadiscovery enters clinical simulation collaboration with Takeda
This agreement builds on an existing relationship between the companies that began in 2017
Manufacturing
Future thoughts about pharmaceutical manufacturing
COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Manufacturing
Takeda opens cell therapy manufacturing facility in Boston
The next-generation cell therapies will initially focuse on oncology with potential to expand into other therapeutic areas
Subscribe now